CLAIMS

1. A compound of Formula (III):



(III),

or a pharmaceutically acceptable salt thereof,

wherein:

B^{1C} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy, , , , an optionally substituted N-linked amino acid, and an optionally substituted N-linked amino acid ester derivative; or

R^{1C} is  and R^{2C} is O^- or OH;

R^{3C} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted –O–C_{1-6} alkyl, an optionally substituted –O–C_{3-6} alkenyl, an optionally substituted –O–C_{3-6} alkynyl, and cyano;

R^{4C} is selected from the group consisting of OH, –OC(=O)$R^{"C}$, and an optionally substituted O-linked amino acid;

R^{5C} is halogen;

R^{6C} is hydrogen or halogen;

R^{9C}, R^{10C}, R^{12C}, and R^{13C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, and an optionally substituted aryl;

R^{11C} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl, and an optionally substituted –O–aryl;

R^{15C} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, and an optionally substituted aryl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and

when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

$R^{"C}$ is an optionally substituted C_{1-24} alkyl;

n is 0 or 1; and

Z^{1C} is O or S.

2. A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{1C} is O^- or OH.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{1C} is an optionally substituted C_{1-6} alkoxy.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{1C} is



.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{1C} is



.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2C} is O^- or OH.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2C} is an optionally substituted C_{1-6} alkoxy.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2C} is



.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2C} is



.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the N-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the N-linked amino acid ester is ,

wherein

R^{19C} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl), and an optionally substituted haloalkyl;

R^{20C} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl, and an optionally substituted aryl(C_{1-6} alkyl); and

R^{21C} is hydrogen or an optionally substituted C_{1-4} alkyl; or

R^{20C} and R^{21C} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine, and norleucine.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ------- is a single bond such that Formula (III) has the structure , wherein each R^{7C} and each R^{8C} is independently hydrogen or halogen.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ------- is a double bond such that Formula (III) has the structure , wherein each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen.

16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein both R^{8C} groups are hydrogen.

17. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein one R^{8C} is halogen and the other R^{8C} is hydrogen.

18. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein both R^{8C} groups are halogen.

19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B^{1C} is selected from the group consisting of:

, , , , , and ;

wherein:

R^{AC2} is selected from the group consisting of hydrogen, halogen, and NHR^{JC2}, wherein R^{JC2} is selected from the group consisting of hydrogen, $-C(=O)R^{KC2}$, and $-C(=O)OR^{LC2}$;

R^{BC2} is halogen or NHR^{WC2}, wherein R^{WC2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{MC2}$, and $-C(=O)OR^{NC2}$;

R^{CC2} is hydrogen or NHR^{OC2}, wherein R^{OC2} is selected from the group consisting of hydrogen, $-C(=O)R^{PC2}$, and $-C(=O)OR^{QC2}$; R^{DC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, and an optionally substituted C_{2-6} alkynyl;

R^{EC2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{RC2}$, and $-C(=O)OR^{SC2}$;

R^{FC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, and an optionally substituted C_{2-6} alkynyl;

Y^{2C} and Y^{3C} are independently N or CR^{IC2}, wherein R^{IC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, and an optionally substituted C_{2-6} alkynyl;

R^{GC2} is an optionally substituted C_{1-6} alkyl;

R^{HC2} is hydrogen or NHR^{TC2}, wherein R^{TC2} is selected from the group consisting of hydrogen, $-C(=O)R^{UC2}$, and $-C(=O)OR^{VC2}$; and

R^{KC2}, R^{LC2}, R^{MC2}, R^{NC2}, R^{PC2}, R^{QC2} R^{RC2}, $R^{SC2,}$ R^{UC2}, and R^{VC2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), and heteroalicyclyl(C_{1-6} alkyl).

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

, and

,

and pharmaceutically acceptable salts of any of the foregoing.

21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:


,

,

, and

,

and pharmaceutically acceptable salts of any of the foregoing.